Navigation Links
Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
Date:2/12/2008

s and explore new biotherapeutic opportunities."

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its pivotal phase III clinical trial in Israel, the United States and other locations for its lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies and products under development
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Protalix BioTherapeutics Announces Resignation of Board Members
2. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
3. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
4. AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors
5. Natural Alternatives International, Inc. Appoints New Chief Financial Officer
6. Deerfield Spa Appoints New Fitness Director
7. Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
8. P\S\L Group appoints Paul Barnes as Group President P\S\L Research
9. AtriCure Appoints Mark A. Collar to its Board of Directors
10. Nastech Appoints MDRNA, Inc. Directors Strategic Advisory Board
11. Milestone Scientific Appoints Dental Industry Veteran Scott Mahnken as New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent ... – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic ... , Clinical trial sites can now use audio, video and interactivity ...
(Date:8/29/2015)... ... 29, 2015 , ... Targeted therapies, made possible by a ... patients, according to a newly published report. Surviving Mesothelioma has more on the ... , The authors of the new paper focus on several types of targeted ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced ... Arterosil and Arterosil HP, and that all claims and counterclaims have been irrevocably ... LLC (VHS) in the United States District Court for the Southern District of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists are ... children helping children, a thank you to the many creative and generous ways ... the United Methodist initiative to end malaria deaths. , The Columbus Zoo and ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3
... found those with multiple auras had seizures arising from one ... People with epilepsy who experience multiple types of auras may ... arise from one area of the brain, a U.S. study ... of Neurology , ,included 31 epilepsy patients who experienced ...
... also been linked to Alzheimer,s, researchers note , FRIDAY, ... apolipoprotein E (APOE) e4 gene variant -- associated with ... types of dementia -- are more likely to develop ... gene variant, a U.S. study finds. , Researchers at ...
... The female sex hormone estrogen turns on a gene linked ... , The cancer biology team from UQ,s Diamantina Institute ... help explain the link between breast cancer and high levels ... ability of estrogen to switch this gene on is important ...
... THURSDAY, Aug. 23 (HealthDay News) -- After a heart attack, ... a new study finds. , In fact, recent heart attack ... diabetes compared with the general population and more than 15 ... the report in the Aug. 25 issue of The ...
... The smell fades with time, study shows , THURSDAY, Aug. ... can affect drinking water,s odor but not for long, a ... instead of copper piping, and scientists are trying to evaluate ... In this study, researchers evaluated several types of plastic piping. ...
... from the Sahlgrenska Academy has established that surgery reduces ... follow up has shown that mortality is significantly lower ... do not. , The results are published today ... show for the first time that surgery against obesity ...
Cached Medicine News:Health News:Some Epilepsy Patients Are Good Candidates for Surgery 2Health News:Gene Tied to Post-Op Delirium in Elderly 2Health News:Heart Attack Boosts Diabetes Risk 2Health News:Surgery for severe obesity saves lives 2
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... 2015  IP Shakti, LLC, today announced that it has ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... corporate identity signifies our transformation into a company focused on ... for patent claim validity." ... AIA Shield™ platform, the Company commenced a corporate re-branding initiative ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Heska Corporation (NASDAQ: HSKA ), a provider ... , today announced that Robert Grieve, Heska,s Chairman and CEO, ... 2011 at 10:30 a.m. PT / 1:30 p.m. ET.  The ... Hotel in Los Angeles. (Logo: http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
... Md., Sept. 13, 2011 Sodexo, Inc., a leader ... with Healthsense, Inc.  As a part of the agreement, ... existing senior living client communities – expanding Sodexo,s current ... Life for all of the people and communities they ...
Cached Medicine Technology:Heska to Present at LD MICRO Invitational on September 22, 2011 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3
... Single Use linear stapler with LACTOMER™ ... Suture™ PREMIUM POLY CS™-57 disposable surgical ... of a temporary opening, such as ... section, or when transecting muscle tissue, ...
... Units With Titanium Staples for ... (Single Use Reloadable Stapler with ... Suture™ PREMIUM MULTIFIRE TA™ stapler ... pediatric and thoracic surgical procedures ...
... Single Use Loading Units for ... (Single Use Reloadable Staplers with ... Suture™ TA™ Reloadable staplers has ... and thoracic surgical procedures for ...
... linear stapler for resection, transection and anastomosis ... MULTIFIRE GIA™ 60 and 80 single use ... 80 single use loading units and the ... use surgical stapler with MULTIFIRE SGIA™ 60 ...
Medicine Products: